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To verify the correlations between the clinical outcomes and physical factors of short-course
chemoradiotherapy (SCRT) and long-course chemoradiotherapy (LCRT) with delayed surgery in
patients with rectal cancer. Seventy-two patients with rectal cancer were enrolled in this study.
Nineteen patients were treated with SCRT (25 Gy, 5 fractions) by intensity-modulated radiation
therapy (IMRT), and 53 patients were treated with LCRT (50.4 Gy, 28 fractions) by threedimensional conformal radiation therapy (3DCRT). Various physical factors for the target and organs
at risk (OARs) were calculated to compare the clinical outcomes. The organ equivalent dose (OED)
and lifetime attributable risk (LAR) of bowels and bladders were similar between the SCRT and
LCRT groups, whereas the values of femurs were higher in the LCRT group. The equivalent
uniform dose and normal tissue complication probability were higher in the LCRT than the SCRT
group for most organs. Treatment complications, including anastomotic leakage, bowel adhesion,
and hematologic toxicity, were not significantly different between SCRT and LCRT groups. CIs
were 0.84±0.2 and 0.61±0.1 for SCRT and LCRT, respectively. The CVIs were 1.07±0.0 and
1.10±0.1, and the HIs were 0.09±0.0 and 0.11±0.1 for SCRT and LCRT, respectively. The
sphincter-saving rates were 89.5% and 94.3% for SCRT and LCRT, respectively. The complete
pathologic remission rates were 21.1% and 13.2%, and the down-staging rates were 47.4% and
26.4% for SCRT and LCRT, respectively. SCRT with IMRT is comparable to conventional LCRT in
both physical indexes and clinical outcome. The preoperative SCRT, compensated by IMRT, is an
effective and safe modality.

Keywords: Chemoradiotherapy, Preoperative treatment, Rectal cancer, Physical Index, Short
course

Introduction

diation therapy-based SCRT compared with those of conventional radiotherapy (RT). Conventional preoperative

Concerns about the complications and lifelong conse-

RT, which is the standard treatment for stage II/III rectal

quences of short-course chemoradiotherapy (SCRT) with

cancer patients, takes 6 weeks to complete and normally

delayed surgery for patients with locally advanced rectal

delivers 50.4 Gy of radiation to the patient. Compared with

cancer led us to verify the correlations between clinical

long-course chemoradiotherapy (LCRT), SCRT takes only

outcomes and physical factors of intensity modulation ra-

a week and delivers approximately 25 Gy, having the dose
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and shortening the length of treatment by 6 times. This is

Chemotherapy was a 350 mg/m2 bolus 5-fluorouracil and

important because the longer the treatment duration, the

20 mg/m2 bolus leucovorin (FL) in the first and last week

greater the decrease in the patient’s strength. Moreover,

during radiotherapy for LCRT. For SCRT, a 400 mg/m2 bo-

less radiation is delivered to patients, which is expected

lus of leucovorin was injected on the 1st day of radiother-

to lead to a lower occurrence of radiation-induced com-

apy, and 1200 mg/m2 of 5-fluorouracil was administered

plications. Based on research conducted by the Dutch

by continuous infusion on the 1st and 2nd days. Between

Colorectal Cancer Group and the Swedish Rectal Cancer

radiotherapy and surgery, 3 cycles of chemotherapy were

Trial, short-course radiotherapy can reduce the risk of local

administered at fortnightly intervals. The treatment type

recurrence.

1)

depends on the RT regimen preference of the surgeon, and

Nonetheless, short-course treatment is not the best treat-

most outpatients who traveled a long distance to the hospi-

ment option in every aspect. Without sufficient time al-

tal were given SCRT. The multi-fraction schedule for SCRT

lowed for tumors to shrink to a more desirable size, there

and LCRT were 25 Gy in 5 fractions and 50.4 Gy in 28 frac-

is a smaller chance of pathological complete remission

tions, respectively. Because it delivers an approximately 3

2)

or downstaging after surgery. Therefore, our institution

times higher dose per fraction, SCRT was delivered with an

has adopted concurrent chemoradiotherapy followed by

IMRT technique to achieve a dosimetric advantage with

delayed surgery to compensate for the lower probability

normal tissue sparing, while LCRT was conventionally

of pathological complete remission after short-course

delivered using a 3D-CRT technique. Assuming an alpha-

3,4)

The 2-year overall survival after SCRT is similar to

beta ratio of 1, the biologically effective dose (BED)-based

but lower than that after LCRT, and other clinical indexes

prescription dose of SCRT is 53.6 Gy, which is comparable

including pathological complete remission, downstaging,

to the prescription dose of LCRT. Patients were treated in

complications, and sphincter-preserving rate are not sig-

the prone position with a belly board. The planning target

RT.

5)

nificantly different after the two treatment approaches.

volume (PTV) and organs at risk (OARs) were contoured

Overall, SCRT is a reasonable and safe option for locally

according to guidelines of the International Commis-

advanced rectal cancer treatment.6-8) However, its effective-

sion on Radiation Units and Measurements Report 50. All

ness on physical aspects must be validated because the

plans were created using ECLIPSE version 8.9 software,

low fractionation number may cause radiation-induced

and calculated results were obtained using a 1 mm grid

disadvantages. Xiangkui et al. reported that shortening

resolution and AAA dose calculation algorithm. Nine to

fraction time can harm normal tissues, which have lower

eleven fields were used in IMRT plans with photon energy

9)

DNA repair capacity. Therefore, unlike the conventional

of 10MV in most cases, whereas three fields were used in

treatment scheme using three-dimensional conformal ra-

3D-CRT plans mostly with parallel opposite fields of 10 MV

diotherapy (3D-CRT), at our institution, short-course treat-

and single Posterior-Anterior (PA) field of 6 MV. In IMRT

ment is delivered with intensity modulated radiation thera-

optimization, dose objectives were set according to the

10-13)

The aim of this study

Emami normal tissue tolerance table. For both IMRT and

was to verify the correlations between clinical outcomes

3D-CRT, plan quality was confirmed before treatment de-

and physical factors of short-course chemoradiotherapy

livery based on the table. Treatments were delivered using

(SCRT) and long-course chemoradiotherapy (LCRT) with

a Varian 21iX linear accelerator and Millennium 120-leaf

delayed surgery in rectal cancer patients.

MLC. Curative surgery was performed 8 weeks after com-

py (IMRT) to spare normal tissue.

pleting the CRT schedule in both groups to allow for tumor
shrinkage. Adjuvant chemotherapy was routinely recom-

Materials and Methods

mended 4 weeks after surgery. There were no noteworthy
Seventy-two patients with rectal cancer who underwent
preoperative chemoradiotherapy followed by curative
surgery between March 2010 and June 2015 were enrolled.

differences in tumor characteristics between the two CRT
groups (Table 1).
To examine the correlations between physical factors

www.ksmp.or.kr
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Table 1. Patient and treatment plan characteristics.
Factor
Age
<70
≥70
Prescribed dose
Gy
BED
Gy
Dose per fraction
Gy
Normalization
%
PTV
Volume (cm3)
D98 (%)
D50 (%)
D2 (%)

sex.

Short course (n=19) Long course (n=53)

To calculate LAR, an organ equivalent dose (OED) was
preliminarily calculated. A plateau dose-response curve

5 (m=73.7)
14 (m=58.3)
25
150
5
96

12 (m=76.8)
41 (m=57.6)

was used:
OED 

50.4
141

1
V

V

i

(1  exp(Di ))

i



where V is total body volume, Vi is volume element with
homogeneous dose, and a different δ of 5.1, 0.26, and 0.096

1.8

was applied for the bladder, bowel, and femur, respectively.
Thus, OED is proportional to cancer risk because it is a

96

dose-response weighted dose variable.
1109
95
100
104

985
93
100
104

Excess absolute risk (EAR) and excess relative risk (ERR)
were calculated using the OED given above. The ERR represents the ratio of the age-specific increase in cancer rate

LAR, lifetime attributable risk; OED, organ equivalent dose; m,
mean value; PTV, planning target volume; D98/50/2, dose covering
98%/50%/2% of PTV; BED, Biologically effective dose.

attributable to a radiation dose divided by the baseline
rate, which is associated with the background radiation
level, whereas EAR is simply the difference in rates attributable to radiation. EAR and ERR are functions of age and

and clinical output, both long-course and short-course

sex and are described as follows:19)

radiotherapy plans were analyzed. The OARs were left and
right femoral heads, bladder, and bowel. Rectal dermatitis,

EAR (d, s, e, a) or ERR (d, s, e, a)=b sdexp (ge*) (a/60)η

colitis, and bloody excrement were typical acute compliwhere e*=

cations of rectal cancer RT, and most patients recovered
several weeks after completing treatment. There also are
chronic side effects such as secondary radiation-induced

min (e, 30)−30
10

β s, γ , and η varied with the model type. For ERR models,
β is the ERR per Sv at age-at-exposure 30 and attained age

cancers, intestinal obstructions, and enterobrosia.
Because life expectancy is increasing yearly and South

60. β varies according to the sex of the patient, and it tends

Korea has the 11th highest life expectancy in the world, life

to be larger for women than men; β s for men/women were

time attributable risk (LAR) was calculated for 19 short-

0.63/0.43 for the bowel and 0.5/1.65 for the bladder, respec-

course and 53 long-course radiotherapy plans to verify the

tively. The γ value implies that radiogenic risk of cancer at

lifelong influence of a shortened RT schedule.14) The ratio

age e falls for every decade increase in age-at-exposure; γ

of patients enrolled in this study under 70 years to over 70

of the bowel and bladder were both −0.3. η implies that the

years was 2.8 and 3.4 in the short-course and long-course

relative amount of ERR is smaller at the attained age; η of

treatment groups, respectively. For LAR calculations, the

the bowel and bladder were both −0.3. Consequently, ERR

risk from age at exposure up to 110 years was integrated,

decreases with age-at-exposure and attained age. In con-

and an EPA (Environmental Protection Agency) approach

trast, for EAR models, η =6 for all OAR except for the bowel

was applied. Separate evaluations of LAR were made using

(η =2.8) and γ =−0.41 for all OAR. Thus, EAR decreases with

both an excess absolute risk model and an excess relative

age-at-exposure but increases with attained age.

risk model.15-17) Rectal cancer-specific incidence and mor-

Effective uniform dose (EUD) facilitates analysis of dose

tality rates were based on the Surveillance, Epidemiology,

inhomogeneity within an organ volume by assuming uni-

and End Results program of the National Cancer Insti-

form dose distribution in organs. EUD was analyzed for

tute.

18)

Different mortality rates were applied depending on

both planning target volume (PTV) and OARs. EUD-based

www.ksmp.or.kr
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normal tissue complication probability (NTCP) was also
20)

calculated for OARs using the Niemierko model:
NTCP=1/(1+ (

bowel were 17.5±3.7 Gy, 17.1±3.3 Gy, 26.7±5.8 Gy, and
5.6±3.9 Gy, respectively, in the short-course CRT group and
22.8±9.4 Gy, 22.3±8.9 Gy, 27.8±11.6 Gy, and 4.5±4.3 Gy in

TD50 4g50
) )
EUD

the long-course CRT group. The bowel had a 1.1 Gy higher
uniform dose in the short-course group. Overlapping vol-

where TD50 is tolerance dose for the 50% complication
rate at a specific time interval when the whole OAR is
homogeneously irradiated, and γ50 is a unitless model parameter that is specific to the normal structure or tumor of

Table 2. Dosimetric factors and clinical outcomes according to
radiation group.

interest.

factor

Conformity index (CI=V95

2
PTV

/VPTV×V95), homogeneity

index (HI=|D2−D98|/D50), and coverage index (CVI=V95PTV/
VPTV) were calculated for PTV to describe the accordance of
the 95% isodose line and the PTV contour, the uniformity
of dose distribution in PTV, and the PTV volume receiving
more than 95% of the prescribed dose, respectively.
Toxicity was scored according to the National Cancer
Institute Common Terminology for Adverse Events version
3.0.

Results
Table 2 shows the clinical output, physical factors, and
P values for LAR, OED, EUD, NTCP, CI, CVI, HI, local recurrence, complete remission, and distant metastasis for
both SCRT and LCRT. The OED values of the LCRT group
were 1E-01±8E-02 Gy, 2E-01±1E-02 Gy, 0.64±0.88 Gy, and
0.64±0.88 Gy for bowel, bladder, left femur, and right femur,
respectively. The OED values of the short-course group
were 1E-01±7E-02 Gy, 2E-01±1E-02 Gy, 0.45±0.11 Gy, and
0.44±0.11 Gy in the same order. Because OED is proportional to LAR, LAR has a similar tendency to OED in that
bowel and bladder values are similar between the shortand long-course groups and femurs have larger values in
the long course group. For the long-course group, LAR was
3E+02±3E+02, 4E+02±3E+01, 21.89±29.80, and 21.76±29.77
for bowel, bladder, left femur, and right femur, respectively. The LAR values of the short-course group were
3E+02±2E+02, 4E+02±2E+01, 15.45±3.90, and 15.07±3.68 in
the same order (Table 2).
EUD was relatively higher for LCRT than SCRT in most
organs except the bowel, as shown in Table 2. EUD values
of the left femoral head, right femoral head, bladder, and

LAR
Bladder
Bowel
LT Femur
RT Femur
OED
Bladder
Bowel
LT Femur
RT Femur
EUD (Gy)
Bladder
Bowel
LT Femur
RT Femur
NTCP (%)
Bladder
Bowel
LT Femur
RT Femur
CI
PTV
CVI
PTV
HI
PTV
Local recurrence
Yes
No
Complete remission
Yes
No
Distant metastasis
Yes
No

Short course
(n=19)

Long course
(n=53)

P

4E+02
3E+02
15.45
15.07

4E+02
3E+02
21.89
21.76

0.294
0.248
0.235
0.235

2.E-01
1E-01
0.45
0.44

2.E-01
1E-01
0.64
0.64

0.303
0.242
0.235
0.235

26.75
5.59
17.51
17.05

27.83
4.47
22.84
22.26

0.248
0.254
0.236
0.241

5E-07
5E-13
8E-09
4E-09

6E-06
1E-10
5E-05
4E-06

0.305
0.241
0.357
0.280

0.84

0.61

0.302

1.10

1.07

0.415

0.09

0.11

0.645
0.442

1
18

12
41

4
15

7
46

0.465

0.162
1
18

12
41

LAR, lifetime attributable risk; OED, organ equivalent dose;
EUD, effective uniform dose; NTCP, normal tissue complication
probability; CI, conformity index; CVI, coverage index; HI,
homogeneity index.

www.ksmp.or.kr
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umes between bowel-PTV and bowel-volume covered by
3

the prescription percentage dose were 46.2±56.4 cm and
3

3

3

147

patient experienced grade 4 anastomosis site leakage, 1
(1.9%) patient experienced grade 3 diarrhea toxicity and

43.6±58.6 cm , 49.0±5.05 cm , and 61.0±61.8 cm for the

bowel adhesion, and 5 (9.4%) patients experienced grade 3

short- and LCRT groups, respectively. The general limita-

anastomosis site leakage.

tions for the entire femoral head, bowel, and bladder proposed by Emami et al. are D100 (defined as minimum dose

Discussion

covering 100% of organ volume) <52 Gy, V50 (percentage of
volume receiving 50Gy) <5%, and V50 <50%, respectively;

The aim of this study was to verify the correlations be-

thus, the EUDs of all OARs are below the level considered

tween clinical outcomes and physical factors of SCRT and

risky.

21)

The SCRT group had lower NTCP values in every

OAR.

LCRT with delayed surgery in patients with rectal cancer. In
a previous clinical study, preoperative SCRT and delayed

NTCP values for the left femoral head, right femoral

surgery for locally advanced rectal cancer were confirmed

head, bladder, and bowel were 8E-09±1E-08, 4E-09±7E-09,

to have clinical effectiveness comparable to that of conven-

5E-07±9E-07, and 5E-13±2E-12, respectively, in the SCRT

tional CRT. In accordance with the results of that previous

group and 5E-05±3E-04, 4E-06±1E-05, 6E-06±1E-05, and

study, this study supports the rationality of SCRT for rectal

1E-10±8E-10 in the LCRT group. CIs were 0.84±0.2 and

cancer treatment in terms of physical aspects.

0.61±0.1 for the SCRT and LCRT groups, respectively, and

In this study, we found that SCRT with delayed surgery

CVIs were 1.07±0.0 and 1.10±0.1. Because variance less

led to pathologic response and down staged rates compa-

than 1 is desirable for both CI and CVI, SCRT has a rela-

rable to those of LCRT for patients with stage II or III rectal

tively better tendency compared to the conventional 3D-

cancer. Physical factors for targets such as BED-based pre-

CRT technique LCRT, but the difference is minimal when

scription dose, CI, CVI, and HI were also found to be con-

considering the error. HI, with an ideal value of zero, was

sistent with clinical outcomes.

0.09±0.0 and 0.11±0.1 for the SCRT and LCRT groups, respectively.

When patients of the SCRT group were treated with the
IMRT technique, the average LAR of femurs was lower

Complete remission was observed in 4 (21.1%) SCRT

than that in patients of the LCRT group, and the average

cases and 7 (13.2%) LCRT cases. Downstaging was ob-

LARs of bowel and bladder were similar to that of patients

served in 9 (47.4%) SCRT cases and 14 (26.4%) LCRT cases.

in the LCRT group. This difference in LARs is because of

Negative circumferential resection margin was observed in

the diverse angle distribution and multi-leaf collimator

17 (89.5%) SCRT cases and 47 (88.7%) SCRT cases. There

movement of IMRT that leads to higher conformity of the

was 1 (5.3%) SCRT case after 28 months and 1 (1.9%) LCRT

prescribed dose to the tumor volume, resulting in low dose

case after 9 months with locoregional recurrence. There

irradiation to OARs. In other words, the dosimetric superi-

was 1 (5.3%) SCRT case and 12 (22.6%) LCRT cases with

ority of IMRT over 3D-CRT may compensate for the poten-

distance metastasis (DM). The 2-year disease-free-survival

tial radiological disadvantages of SCRT. Compared with the

(DFS) rate was 93.8% in the SCRT group and 74.0% in the

conventional treatment scheme, half of the prescription

LCRT group. Twenty year overall survival (OS) was 90.0%

dose is delivered on a 1/6 timescale in SCRT. This compar-

with SCRT and 91.2% with LCRT. Two patients died at 22

atively intensive dose delivery may have radiological disad-

months and 39 months after SCRT. Four patients were

vantages. The correlations between clinical outcomes and

dead at 24 months after LCRT, and 1 patient died at 52

LAR in SCRT and LCRT are difficult to identify at this stage

months. With SCRT, 1 patient (5.6%) experienced grade 4

because of the longer follow-up period and large amount

anastomosis site leakage requiring surgical intervention,

of statistically significant patient data required.

1 (5.6%) patient experienced grade 3 hematologic toxicity

Bowel EUD was relatively higher with SCRT, although

and bowel adhesion, and 3 (16.7%) patients experienced

the other OARs had smaller EUD values than LCRT. Mean-

grade 3 anastomosis site leakage toxicity. In LCRT, 1 (1.9%)

while, EUD-based NTCPs were smaller with SCRT for all

www.ksmp.or.kr
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OARs. Because of certain dosimetric characteristics of the

However, the benefit of adding chemotherapy to SCRT

bowel, partial high dose irradiation has a greater risk for

is not clear. The present study showed superior outcomes,

radiation-induced complications, such as enterobrosis,

with a downstaging rate of 47.4% and a complete remission

than low dose irradiation.

rate of 21.1% in the SCRT group and feasible toxicities, with

Other OARs for the bladder and femoral heads had lower

1 patients experienced grade 3 hematologic toxicity in the

EUDs and NTCPs in SCRT because these organs are located

SCRT group. So, we elicit that concurrent chemotherapy

in the typical 3D-CRT beam route. In conventional long-

with SCRT and an additional 3 cycles of chemotherapy be-

course 3D-CRT, a three-channel (left lateral, right lateral,

fore surgery may be able to consolidate treatment.

post-anterior [PA]) box plan is the general plan for rectal
cancer. The femoral heads and bladder are located in the

Conclusion

lateral and PA beam routes, respectively. However, in shortcourse IMRT, the radiation is less concentrated in OARs be-

SCRT with IMRT is slightly better or comparable to

cause the beams are distributed in multiple directions. This

conventional LCRT in both physical indexes and clinical

enables higher PTV conformity and lower OAR exposure.

outcome. Preoperative short-course CRT, compensated by

Toxicities according to radiation groups are summarized

IMRT, is an effective and safe modality.

in Table 3. Grade 3 or 4 anastomosis site leakage requiring
surgical intervention was noted in 4 (21.1 %) patients with
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